AMY1-3 bind pramlintide

Stable Identifier
Reaction [binding]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Amylin (Islet amyloid polypeptide, AIPP(34-70)) is a 37-residue peptide hormone which belongs to the calcitonin peptide family. It is cosecreted with insulin from pancreatic β-cells and plays a role in glycemic regulation by preventing post-prandial spikes in blood glucose levels. Its effects are mediated via binding to three distinct receptor complexes containing the calcitonin receptor, plus one of three receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.

Pramlintide is a synthetic analogue of human amylin with proline substitutions in positions 25, 26 and 29. Its actions are mediated through calcitonin-RAMP receptor complexes (Gingell et al. 2014). Pramlintide is approved for use in patients with both diabetes mellitus type 1 and diabetes mellitus type 2 (Schmitz et al. 1997, Edelman et al. 2008). Structure-function relationships of amylin are being used for the development of newer amylin mimetic drug (Bower & Hay 2016).
Literature References
PubMed ID Title Journal Year
24169554 Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors

Hay, DL, Gingell, JJ, Burns, ER

Endocrinology 2014
9212325 Effects of amylin and the amylin agonist pramlintide on glucose metabolism

Gravholt, C, Nyholm, B, Møller, N, Schmitz, O, Orskov, L

Diabet Med 1997
Orthologous Events
Cite Us!